PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30456449-8	2019	In the presence of TNF-alpha, VPA inhibited the induction of specific cytokines/chemokines, notably CCL5 and VEGF-A, as well as NF-kB2 p100.	Valproic Acid	30-33	tumor necrosis factor	Mus musculus	19-28	
30456449-9	2019	In corroboration, VPA suppressed TNF-alpha stimulation of NF-kB reporter transcription by 1.51-fold.	Valproic Acid	18-21	tumor necrosis factor	Mus musculus	33-42	
30456449-15	2019	VPA suppressed TNF-alpha induction of chemokines, cytokines and NF-kB2 p100 expression.	Valproic Acid	0-3	tumor necrosis factor	Mus musculus	15-24	
30456449-16	2019	VPA suppressed TNF-alpha stimulation of NF-kB reporter.	Valproic Acid	0-3	tumor necrosis factor	Mus musculus	15-24	
26196351-9	2015	MEASUREMENTS AND MAIN RESULTS: Valproic acid and BAY11-7082 selectively diminished tumor necrosis factor-alpha-induced endothelial proinflammatory activation in vitro.	Valproic Acid	31-44	tumor necrosis factor	Mus musculus	83-110	
30166610-14	2018	modulated oxidative stress status by increasing GSH and decreasing MDA, and it attenuated the proinflammatory cytokines IL-1beta, IL-6 and TNF-alpha exacerbated by lipopolysaccharide (LPS) challenge, in VPA-exposed mouse brain tissue.	Valproic Acid	203-206	tumor necrosis factor	Mus musculus	139-148	
27639185-6	2017	Upon stimulation of immature DC with LPS, VPA, and lithium both reduced the secretion of IL-6 and TNF-alpha.	Valproic Acid	42-45	tumor necrosis factor	Mus musculus	98-107	
34032977-12	2021	Our data suggest which necroptosis has a key role in the toxicity of VPA through TNF-alpha-mediated RIPK1/RIPK3/MLKL signaling and oxidative stress.	Valproic Acid	69-72	tumor necrosis factor	Mus musculus	81-90	
24948542-6	2014	After treatment with VPA, the renal level of malondialdehyde and the activity of myeloperoxidase decreased markedly; the activity of superoxide dismutase and the glutathione content increased accordingly; and the serum levels of tumor necrosis factor alpha, interleukin 1beta, and interleukin 6 decreased markedly.	Valproic Acid	21-24	tumor necrosis factor	Mus musculus	229-256	
24854198-5	2015	Moreover, the extensive astrogliosis and microgliosis as well as the increased expression in interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) in the hippocampus and cortex of APP/PS1 transgenic mice were significantly reduced following administration of VPA, which attenuated neuronal degeneration.	Valproic Acid	278-281	tumor necrosis factor	Mus musculus	126-153	
24854198-5	2015	Moreover, the extensive astrogliosis and microgliosis as well as the increased expression in interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) in the hippocampus and cortex of APP/PS1 transgenic mice were significantly reduced following administration of VPA, which attenuated neuronal degeneration.	Valproic Acid	278-281	tumor necrosis factor	Mus musculus	155-164	
23159286-8	2012	RESULTS: MTX alone or VPA alone induced a significant increase in tissue CAT and GR with a significant decrease in the tumour volume, tissue MDA, cholesterol and TNF-alpha and alleviated the histopathological changes with a significant increase in p53 expression compared to SEC group.	Valproic Acid	22-25	tumor necrosis factor	Mus musculus	162-171	
35451424-13	2022	Besides, apelin-13 decreased the enrichment of H3K9ac at the promoter region of TNF-alpha and IL-6 to inhibit inflammatory response, which was reversed by histone deacetylase antagonist valproate.	Valproic Acid	186-195	tumor necrosis factor	Mus musculus	80-89	
33224434-9	2020	VPA administration significantly decreased the expression of phosphorylated nuclear factor-kappa B (p-NFkappaB), matrix metalloproteinases 9 (MMP9), tumor necrosis factoralpha (TNFalpha), and interleukin-6 (IL-6), while it enhanced the expression of claudin 5 and occludin in the brain.	Valproic Acid	0-3	tumor necrosis factor	Mus musculus	149-175	
33224434-9	2020	VPA administration significantly decreased the expression of phosphorylated nuclear factor-kappa B (p-NFkappaB), matrix metalloproteinases 9 (MMP9), tumor necrosis factoralpha (TNFalpha), and interleukin-6 (IL-6), while it enhanced the expression of claudin 5 and occludin in the brain.	Valproic Acid	0-3	tumor necrosis factor	Mus musculus	177-185	
32405761-13	2020	Administration of VAL, DIC, MEL, VAL + MEL and VAL + DIC decreased TNF-alpha, IL-1beta, MDA, and PGE2 levels meanwhile, they increased GSH content in the brain homogenates.	Valproic Acid	18-21	tumor necrosis factor	Mus musculus	67-76	
32405761-13	2020	Administration of VAL, DIC, MEL, VAL + MEL and VAL + DIC decreased TNF-alpha, IL-1beta, MDA, and PGE2 levels meanwhile, they increased GSH content in the brain homogenates.	Valproic Acid	33-36	tumor necrosis factor	Mus musculus	67-76	
32405761-13	2020	Administration of VAL, DIC, MEL, VAL + MEL and VAL + DIC decreased TNF-alpha, IL-1beta, MDA, and PGE2 levels meanwhile, they increased GSH content in the brain homogenates.	Valproic Acid	33-36	tumor necrosis factor	Mus musculus	67-76